{"id":"https://openalex.org/W3095012800","doi":"https://doi.org/10.1182/blood-2020-139945","title":"A High Throughput Functional Screen Identifies a Novel Apex Inhibitor: Augments Cytotoxicity While Significantly Decreasing Genomic Evolution in Myeloma","display_name":"A High Throughput Functional Screen Identifies a Novel Apex Inhibitor: Augments Cytotoxicity While Significantly Decreasing Genomic Evolution in Myeloma","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W3095012800","doi":"https://doi.org/10.1182/blood-2020-139945","mag":"3095012800"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-139945","doi":"https://doi.org/10.1182/blood-2020-139945","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-139945","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112389374","display_name":"Srikanth Talluri","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801671727","display_name":"VA Boston Healthcare System","ror":"https://ror.org/04v00sg98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I2801671727","https://openalex.org/I4210095851"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srikanth Talluri","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA","VA Boston Healthcare System, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"VA Boston Healthcare System, Boston, MA","institution_ids":["https://openalex.org/I2801671727"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027257617","display_name":"Jialan Shi","orcid":"https://orcid.org/0000-0001-5642-5436","observed_orcids":["https://orcid.org/0000-0001-5642-5436"]},"institutions":[{"id":"https://openalex.org/I2801671727","display_name":"VA Boston Healthcare System","ror":"https://ror.org/04v00sg98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I2801671727","https://openalex.org/I4210095851"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jialan Shi","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA","VA Boston Healthcare System, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"VA Boston Healthcare System, Boston, MA","institution_ids":["https://openalex.org/I2801671727"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000397623","display_name":"Mychell A. Neptune","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801671727","display_name":"VA Boston Healthcare System","ror":"https://ror.org/04v00sg98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I2801671727","https://openalex.org/I4210095851"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mychell Neptune-Buon","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA","VA Boston Healthcare System, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"VA Boston Healthcare System, Boston, MA","institution_ids":["https://openalex.org/I2801671727"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103420970","display_name":"Subodh Kumar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801671727","display_name":"VA Boston Healthcare System","ror":"https://ror.org/04v00sg98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I2801671727","https://openalex.org/I4210095851"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Subodh Kumar","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA","VA Boston Healthcare System, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"VA Boston Healthcare System, Boston, MA","institution_ids":["https://openalex.org/I2801671727"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078948384","display_name":"Lakshmi B. Potluri","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801671727","display_name":"VA Boston Healthcare System","ror":"https://ror.org/04v00sg98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I2801671727","https://openalex.org/I4210095851"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lakshmi B. Potluri","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA","VA Boston Healthcare System, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"VA Boston Healthcare System, Boston, MA","institution_ids":["https://openalex.org/I2801671727"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045740077","display_name":"Nikhil C. Munshi","orcid":"https://orcid.org/0000-0002-7344-9795","observed_orcids":["https://orcid.org/0000-0002-7344-9795","https://orcid.org/0000-0002-8397-100X"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I2801671727","display_name":"VA Boston Healthcare System","ror":"https://ror.org/04v00sg98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I2801671727","https://openalex.org/I4210095851"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nikhil C. Munshi","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA","Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","VA Boston Healthcare System, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]},{"raw_affiliation_string":"VA Boston Healthcare System, Boston, MA","institution_ids":["https://openalex.org/I2801671727"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063099799","display_name":"Masood A. Shammas","orcid":"https://orcid.org/0000-0002-8932-6829","observed_orcids":["https://orcid.org/0000-0002-8932-6829"]},"institutions":[{"id":"https://openalex.org/I2801671727","display_name":"VA Boston Healthcare System","ror":"https://ror.org/04v00sg98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I2801671727","https://openalex.org/I4210095851"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Masood A. Shammas","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA","VA Boston Healthcare System, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"VA Boston Healthcare System, Boston, MA","institution_ids":["https://openalex.org/I2801671727"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.16463222,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"136","issue":"Supplement 1","first_page":"10","last_page":"11"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.7817000150680542,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.7817000150680542,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.195700004696846,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9879999756813049},{"id":"https://openalex.org/keywords/apex1","display_name":"APEX1","score":0.8899999856948853},{"id":"https://openalex.org/keywords/genomic-instability","display_name":"genomic instability","score":0.9470000267028809},{"id":"https://openalex.org/keywords/homologous-recombination","display_name":"homologous recombination","score":0.9860000014305115},{"id":"https://openalex.org/keywords/dna-end-resection","display_name":"DNA end resection","score":0.7509999871253967},{"id":"https://openalex.org/keywords/dna-double-strand-breaks","display_name":"DNA double-strand breaks","score":0.6769999861717224},{"id":"https://openalex.org/keywords/g2-m-cell-cycle-arrest","display_name":"G2/M cell cycle arrest","score":0.6759999990463257},{"id":"https://openalex.org/keywords/cyclophosphamide","display_name":"cyclophosphamide","score":0.7099999785423279},{"id":"https://openalex.org/keywords/melphalan","display_name":"melphalan","score":0.996999979019165},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9100000262260437},{"id":"https://openalex.org/keywords/synergistic-drug-combination","display_name":"synergistic drug combination","score":0.652999997138977},{"id":"https://openalex.org/keywords/high-throughput-drug-screening","display_name":"high-throughput drug screening","score":0.4860000014305115}],"concepts":[{"id":"https://openalex.org/C178169997","wikidata":"https://www.wikidata.org/wiki/Q2892636","display_name":"Genome instability","level":4,"score":0.8371049165725708},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5778874158859253},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.5206372141838074},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.4757145047187805},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.46722280979156494},{"id":"https://openalex.org/C162317418","wikidata":"https://www.wikidata.org/wiki/Q252857","display_name":"Transcriptome","level":4,"score":0.41985073685646057},{"id":"https://openalex.org/C143425029","wikidata":"https://www.wikidata.org/wiki/Q5205747","display_name":"DNA damage","level":3,"score":0.38885506987571716},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.2495872676372528},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.2399754822254181},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.13737675547599792},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.08691856265068054},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-139945","doi":"https://doi.org/10.1182/blood-2020-139945","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-139945","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4387003562","https://openalex.org/W2590532285","https://openalex.org/W2577420464","https://openalex.org/W2534637104","https://openalex.org/W2535064360","https://openalex.org/W3084841004","https://openalex.org/W2560598769","https://openalex.org/W2980699639","https://openalex.org/W2921201565","https://openalex.org/W4280601762"],"abstract_inverted_index":{"Multiple":[0],"myeloma":[1,129,189,289],"(MM)":[2],"is":[3],"molecularly":[4],"heterogenous":[5],"disease":[6],"with":[7,187,258,293,338,424,453,458],"significant":[8,359],"genomic":[9,36,82,117,287,335,354,484],"instability.":[10,460],"It":[11],"carries":[12],"number":[13,396,436],"of":[14,35,62,78,109,142,157,196,216,234,251,284,308,319,324,334,388,393,433,477,520],"mutations":[15],"at":[16],"diagnosis":[17],"(median":[18],">":[19,441],"7000)":[20],"and":[21,66,88,93,116,124,139,152,173,176,198,226,229,244,298,326,390,457],"acquires":[22],"additional":[23],"changes":[24,397],"overtime.":[25],"With":[26],"this":[27],"background,":[28],"we":[29,46,97,144],"have":[30,47,98,177],"evaluated":[31,299],"the":[32,171,232,317,373,378,384,391,407,421,431,478],"molecular":[33],"intermediates":[34],"instability":[37,118,355],"in":[38,69,90,128,169,185,220,236,256,260,279,316,361,363,366,383,406,427,430,466,486,504,512],"MM.":[39,70,487],"Based":[40],"on":[41,193,209,286,302,375,516],"our":[42],"large":[43],"transcriptomic":[44],"data":[45,446],"identified":[48,162,465],"apurinic/apyrimidinic":[49],"deoxyribonuclease":[50],"(APEX)":[51],"as":[52,104,106,119,130,132,164,182,184,275,277,342,344,351,353,450],"an":[53,165,471,517],"important":[54,472],"target":[55],"whose":[56],"elevated":[57],"activity":[58,115,150],"contributes":[59],"to":[60,85,410,418,440,474],"dysregulation":[61],"homologous":[63],"recombination":[64],"(HR)":[65],"genome":[67,199,327,376,459],"stability":[68,328],"Our":[71],"investigation":[72],"also":[73,230,254],"demonstrates":[74],"that":[75,101],"transgenic":[76,103],"overexpression":[77],"APEX":[79,167,448],"nucleases":[80],"induces":[81,125],"instability,":[83],"leading":[84],"oncogenic":[86],"transformation":[87],"tumorigenesis":[89],"a":[91,146,154,367,467],"murine":[92],"Zebrafish":[94],"models.":[95],"Importantly,":[96],"now":[99,178],"observed":[100,255],"both":[102,170,221],"well":[105,131,183,276,343,352],"chemical":[107],"inhibition":[108],"APEX1,":[110,143],"reduces":[111],"DNA":[112,303,310,346,348],"breaks,":[113,347],"HR":[114],"measured":[120,402],"by":[121,321,329,358],"micronucleus":[122],"assay,":[123],"G2/M":[126],"arrest":[127],"esophageal":[133],"cancer":[134],"cells.":[135,281],"To":[136,370],"identify":[137],"novel":[138,462],"effective":[140,166],"inhibitors":[141],"optimized":[145],"high":[147],"throughput":[148],"APEX1":[149,463],"assay":[151],"screened":[153],"custom":[155],"library":[156],"100,000":[158],"small":[159],"molecules.":[160],"We":[161],"API-93":[163,202,252,339,425],"inhibitor":[168],"primary":[172],"secondary":[174],"screens,":[175],"investigated":[179],"it,":[180],"alone":[181],"combination,":[186],"existing":[188],"drugs,":[190],"for":[191,300],"impact":[192,285,301,374],"different":[194],"parameters":[195],"growth":[197],"maintenance.":[200],"Although":[201],"had":[203],"minimal":[204],"single":[205],"agent":[206,218],"cytotoxic":[207],"effect":[208,250],"MM":[210,222,238,262,280,364,379,454],"cells,":[211,365,420],"it":[212],"synergistically":[213],"increased":[214,231],"cytotoxicity":[215,476],"chemotherapeutic":[217],"cyclophosphamide":[219],"cell":[223,239,263,455],"lines":[224,240,264],"(MM1S":[225],"RPMI)":[227],"tested,":[228],"efficacy":[233],"melphalan":[235],"several":[237],"(RPMI,":[241,266],"MM1R,":[242,268],"KK1":[243],"LR5)":[245],"tested.":[246],"A":[247],"strong":[248],"synergistic":[249],"was":[253],"combination":[257,271],"lenalidomide":[259],"5":[261],"tested":[265],"MM1S,":[267],"KK1,":[269],"H929;":[270],"indexes":[272],"<":[273],"1)":[274],"velcade":[278],"For":[282],"evaluation":[283],"changes,":[288],"cells":[290,296,380,413,422],"were":[291,381,401],"treated":[292,423],"API-93,":[294,389],"live":[295],"purified":[297],"breaks":[304],"(by":[305],"measuring":[306],"levels":[307,323],"\u03b3-H2AX),":[309],"end":[311,349],"resection":[312,350],"(a":[313],"decisive":[314],"step":[315],"initiation":[318],"HR,":[320],"monitoring":[322],"p-RPA32),":[325],"investigating":[330],"micronuclei":[331],"(the":[332],"marker":[333],"instability).":[336],"Treatment":[337],"reduced":[340],"spontaneous":[341],"melphalan-induced":[345],"(as":[356],"assessed":[357],"reduction":[360],"micronuclei)":[362],"dose-dependent":[368,428],"manner.":[369],"further":[371],"confirm":[372],"stability,":[377],"cultured":[382,408],"presence":[385],"or":[386,522],"absence":[387],"acquisition":[392,432],"new":[394,434],"copy":[395,435],"over":[398],"3":[399],"weeks":[400],"using":[403],"SNP":[404],"arrays,":[405],"relative":[409],"Day":[411],"0":[412],"(representing":[414],"baseline":[415],"genome).":[416],"Relative":[417],"control":[419],"resulted":[426],"decrease":[429],"events,":[437],"from":[438],"50%":[439],"90%.":[442],"In":[443],"conclusion,":[444],"these":[445],"demonstrate":[447],"gene":[449],"being":[451],"associated":[452],"survival":[456],"The":[461],"inhibitor,":[464],"functional":[468],"screen,":[469],"provides":[470],"tool":[473],"augment":[475],"current":[479],"therapeutics":[480],"while":[481],"significantly":[482],"decreasing":[483],"evolution":[485],"Disclosures":[488],"Munshi:":[489],"Adaptive:":[490],"Consultancy;":[491,493,495,497,499,529,531],"Takeda:":[492],"Amgen:":[494],"Legend:":[496],"Janssen:":[498],"C4:":[500],"Current":[501,509],"equity":[502,510],"holder":[503,511],"private":[505,513],"company;":[506],"OncoPep:":[507],"Consultancy,":[508],"company,":[514],"Membership":[515],"entity's":[518],"Board":[519],"Directors":[521],"advisory":[523],"committees,":[524],"Patents":[525],"&":[526],"Royalties;":[527],"BMS:":[528],"AbbVie:":[530],"Karyopharm:":[532],"Consultancy.":[533]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2020-11-09T00:00:00"}